EcoDrugPlus

Leukotriene A4 Hydrolase

Ensembl ID : ENSGACG00000000675
Gene Symbol: LTA4H
1 Cross references
205 Possible Orthologues:

Leukotriene B4 Receptor

Ensembl ID : ENSGACG00000018962
Gene Symbol: LTB4R
1 Cross references
142 Possible Orthologues:

Leukotriene B4 Receptor

Ensembl ID : ENSGACG00000018954
Gene Symbol: LTB4R
1 Cross references
142 Possible Orthologues:

Leukotriene B4 Receptor 2a

Ensembl ID : ENSGACG00000018963
Gene Symbol: LTB4R2A
1 Cross references
159 Possible Orthologues:

Lysine (K)-Specific Demethylase 1a

Ensembl ID : ENSGACG00000009679
Gene Symbol: KDM1A
1 Cross references
214 Possible Orthologues:

Lysyl Oxidase-Like 2a

Ensembl ID : ENSGACG00000008420
Gene Symbol: LOXL2A
1 Cross references
208 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSGACG00000005422
Gene Symbol: LOXL2B
1 Cross references
213 Possible Orthologues:

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSGACG00000017868
Gene Symbol: MIF
1 Cross references
235 Possible Orthologues:

Matrix Metallopeptidase 14a (Membrane-Inserted)

Ensembl ID : ENSGACG00000019199
Gene Symbol: MMP14A
1 Cross references
199 Possible Orthologues:

Matrix Metallopeptidase 14b (Membrane-Inserted)

Ensembl ID : ENSGACG00000014069
Gene Symbol: MMP14B
1 Cross references
198 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSGACG00000016670
Gene Symbol: MMP2
1 Cross references
210 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSGACG00000008035
Gene Symbol: MMP9
1 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).